Valuation dashboard for Nanobiotix S.A. (NBTX) with P/E N/A, P/B -15.69, EV/EBITDA -140.35 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Nanobiotix S.A. is a clinical-stage biotechnology firm focused on developing innovative therapeutic solutions for cancer. The company's leading experimental drug, NBTXR3, is a sterile aqueous suspension comprising crystalline hafnium oxide nanoparticles.
Analysis Summary
Nanobiotix S.A. reported revenue of $29.6M in the most recent fiscal year, growing at a 5-year CAGR of 66.4%.
Trailing-twelve-month margins: gross margin 100.0%, operating margin -36.5%, net margin -80.8%.
At the current price of $34.40, NBTX has negative trailing earnings (P/E not meaningful) and an ROE of 31.23%. Market capitalisation stands at $1.7B.
Balance sheet quality for NBTX: current ratio of 1.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -15.69 |
| EV / EBITDA | -140.35 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-3.59 |
| vs Current Price | -110.4% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NBTX | Nanobiotix S.A. | $1.7B | 31.2% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $34.40 |
| Market Cap | $1.7B |
| Exchange | NASDAQ |
| Country | FR |
Profitability
| Return on Equity | 31.23% |
| Return on Invested Capital | -74.29% |
| Return on Assets | -35.36% |
| Gross Margin | 100.00% |
| Operating Margin | -36.49% |
| Net Margin | -80.83% |
Related companies: ABUS · EYPT · GHRS · KURA · LENZ · PROK · RZLT
Explore sector: Healthcare · Biotechnology
More sections of NBTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks